Cite
MLA Citation
Masayuki Takeda et al.. “A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy.” Lung cancer, vol. 177, 2023, pp. 44–50. http://access.bl.uk/ark:/81055/vdc_100177580951.0x00005b